● 变更后的股票证券简称：华润江中， 股票证券代码"600750"保持不变 ● 证券简称变更日期：2026年1月30日 一、公司董事会审议变更证券简称的情况 证券代码：600750 证券简称：江中药业 公告编号：2026-004 华润江中药业股份有限公司 证券简称变更实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次变更公司证券简称有助于强化与华润的品牌协同认知，进一步提升公司品牌辨识度和市场影响力。 该事项不会对公司产生重大影响。 三、公司证券简称变更的实施 经公司申请，并经上海证券交易所办理，公司证券简称将于2026年1月30日起由"江中药业"变更为"华润 江中"，公司证券代码"600750"保持不变。 特此公告。 华润江中药业股份有限公司董事会 2026年1月27日 华润江中药业股份有限公司（以下简称"公司"）于2025年12月12日召开第十届董事会第十次会议、于 2025年12月29日召开了2025年第二次临时股东大会，审议通过了《关于变更公司名称及证券简称、变更 注册资本、取消监事会并修订 ...

Core Viewpoint - Jiangzhong Pharmaceutical (600750) has confirmed that its subsidiary, Jiangzhong Decoction Pieces, primarily serves medical institutions in the Jiangxi region, with related business revenue included in the company's consolidated financial statements [1] Group 1 - The company's decoction business is focused on the Jiangxi region [1] - The brand "Huizhongtang" under Jiangzhong Decoction Pieces has multiple products that have been selected as "Traditional Chinese Medicine Decoction Brand Products" [1] - Currently, the company does not have any overseas business operations [1]

Group 1 - The number of listed companies disclosing data is steadily increasing, indicating a sign of maturity in China's nutrition and health industry [1] Group 2 - Dongpeng Beverage (09980.HK) has announced a global offering of 40.89 million shares, with 4.09 million shares available in Hong Kong and 36.80 million shares for international offering, along with an over-allotment option of 6.13 million shares. The subscription period is from January 26 to January 29, with an expected listing date on February 3 [2] - Jiangzhong Pharmaceutical aims for a net profit of 900 million yuan by 2025 [3] - Angel Yeast plans to invest in a green manufacturing project for yeast products [3] - Ningbo Yujian Health Technology Co., Ltd., a dietary supplement raw material manufacturer, is pursuing a listing on the Beijing Stock Exchange, with continuous growth in revenue and net profit projected from 2022 to 2025 [3]

证券代码：600750 证券简称：江中药业 公告编号：2026-004 华润江中药业股份有限公司 证券简称变更实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、公司董事会审议变更证券简称的情况 华润江中药业股份有限公司（以下简称"公司"）于 2025 年 12 月 12 日召开 第十届董事会第十次会议、于 2025 年 12 月 29 日召开了 2025 年第二次临时股东 大会，审议通过了《关于变更公司名称及证券简称、变更注册资本、取消监事会 并修订<公司章程>的议案》，同意公司将证券简称由"江中药业"变更为"华润江 中"，证券代码仍然为"600750"。 二、公司董事会关于变更证券简称的理由 本次变更公司证券简称有助于强化与华润的品牌协同认知，进一步提升公司 品牌辨识度和市场影响力。该事项不会对公司产生重大影响。 三、公司证券简称变更的实施 经公司申请，并经上海证券交易所办理，公司证券简称将于 2026 年 1 月 30 日起由"江中药业"变更为"华润江中"，公司证券代码"600750"保持不变。 特此公告。 华 ...

Core Viewpoint - Jiangzhong Pharmaceutical (600750.SH) will change its stock name to "China Resources Jiangzhong" effective January 30, 2026, while the stock code "600750" will remain unchanged [1]. Group 1 - The company has applied for the name change and it has been processed by the Shanghai Stock Exchange [1].

每经AI快讯，1月26日，江中药业（600750）公告称，公司证券简称将于2026年1月30日起由"江中药 业"变更为"华润江中"，股票证券代码"600750"保持不变。此次变更有助于强化与华润的品牌协同认 知，进一步提升公司品牌辨识度和市场影响力。 ...

公司在报告期内面临行业结构性调整压力，通过加强品牌打造和优化费用结构等措施，推动了盈利水平 的提升。 （江中药业公告） 近日，江中药业发布公告称，公司实现营业收入42.20亿元，同比减少4.87%；实现归属于上市公司股东 的净利润9.06亿元，同比增长14.96%。 ...

Group 1 - The article highlights the top 20 stocks in the S&P China A-Share Dividend Opportunities Index (CSPSADRP) as of January 23, 2026, showcasing significant price increases and dividend yields [1][11]. - The stock with the highest daily increase is Aotaiwei (688516.CH) at 20.00%, with a year-to-date increase of 98.87% and a dividend yield of 2.80% [1][11]. - Other notable stocks include China Gold (600916.SH) with a daily increase of 10.02% and a year-to-date increase of 13.13%, and Weichai Power (000338.SZ) with a year-to-date increase of 36.63% [1][11]. Group 2 - The fundamental metrics of the index include a historical price-to-earnings ratio of 11.07 times, a price-to-book ratio of 1.34 times, and an expected dividend yield of 4.76% [3][12]. - The index consists of 1009 constituent stocks, with adjustments made biannually in January and July, ensuring no single stock exceeds 3% weight and no GICS sector exceeds 33% weight [4][13].

2025 年盈利同比增长15% 公司发布2025 年业绩快报，预报2025 全年收入42.20 亿元，同比下滑5%，全年归母净利润9.06 亿元， 同比增长15%。 期待"十五五"期间实现稳健可持续增长。2025 年公司围绕"做强OTC、发展健康消费品、布局处方 药"三大业务布局，不断巩固核心竞争力。2025 年下半年公司以自有资金4,000 万元参与设立华润医药 产业投资基金二期，我们认为有望进一步储备与公司战略方向相匹配的项目资源。2026 年为"十五 五"计划开局之年，我们期待公司通过外延+内生实现长期稳健增长。 盈利预测与估值 考虑OTC业务受到宏观医药消费环境负面影响，我们下调25/26年收入6%/6%至42.19/45.13 亿元，引入 2027 年收入预测48.31 亿元，但同时持续推进降本增效盈利能力提升，我们上调25/26 年归母净利润 4%/6%至9.06/10.09 亿元，引入2027 年净利润11.16 亿元。我们维持跑赢行业评级，现价对应26/27 年 P/E为14.7/13.3 倍。同步上调6%目标价至28.90 元，对应26/27 年P/E为18.2/16.4 倍，隐含23.3% ...

Group 1 - The company reported a preliminary financial data for the year 2025, which is subject to final audit and may differ from the final report [1][4] - The company achieved an operating revenue of 4.22 billion yuan, a decrease of 4.87% year-on-year [3] - The net profit attributable to shareholders of the listed company was 906 million yuan, reflecting a year-on-year increase of 14.96% [3] Group 2 - The company is focusing on brand building and strengthening its core business through "big single products and strong categories" [3] - Marketing strategies have been enriched, with an emphasis on return on investment and optimizing cost structures [3] - The company is implementing lean manufacturing to reduce costs and improve efficiency, contributing to the enhancement of profitability [3]